Lumavita tops up its Series A funding with CHF 6 million

Friday 19 June 2009

The Swiss specialty biopharmaceutical company, Lumavita AG, has topped up a recent Series A funding round with CHF 6 million, bringing the total amount raised for commercialising its lead antibiotic product to CHF 24 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland